Mallinckrodt plc’s decade-long frustration with getting approval for its vasopressin analogue selective for V1 receptors, terlipressin, for use in hepatorenal syndrome type 1 continues as the FDA issued the company a third complete response letter (CRL) for the drug.
In the company’s largest acquisition and potentially the fifth biggest biotech M&A ever, Gilead Sciences Inc. will acquire Immunomedics Inc. for $21 billion in a move that substantially transforms Gilead’s oncology portfolio.
Though falling short of the outright takeover that some may have hoped for, Merck & Co. Inc.’s dual tie-ups with Seattle Genetics Inc. (Seagen) put the latter in solid position to shop for acquisitions of its own.
HONG KONG – Interim results of a phase I study CT-P59, an anti-COVID-19 monoclonal antibody being developed by Incheon, South Korea-based Celltrion Inc., have confirmed the candidate’s safety, tolerability and pharmacokinetics in healthy subjects, giving the company confidence to ramp up production of the experimental antiviral.
Ignoring industry’s threat of a lawsuit, U.S. President Donald Trump is moving forward with his plan for “most-favored nation” pricing of certain prescription drugs. The president, on Sept. 13, signed the executive order he threatened in July if industry didn’t come up with a better offer by Aug. 24. Industry did make a counter offer last month, but apparently it wasn’t enough.
HONG KONG – The use of artificial intelligence in drug discovery was back in the spotlight on the last day of the 2020 KoNECT-MOHW-MFDS International Conference, with drug developers pointing out both challenges and possible solutions.
Investors clipped shares of Avadel Pharmaceuticals plc recently as anxieties rose over the application by Jazz Pharmaceuticals plc for a patent that relates to a once-nightly oxybate product that could threaten the prospects for Avadel’s FT-218.
HONG KONG – The Korean 2020 KoNECT-MOHW-MFDS International Conference, which is taking place online this year due to the COVID-19 pandemic, faced a challenging start. Technical difficulties hampered some of the early proceeding. However, technology took focus again later in the day in a more positive, with an exploration of artificial intelligence (AI).
RSS
